Who Paid My Doc
Ming Hao
Geriatric Medicine Saint Louis, MO Medical Doctor
NPI 1861607640 CMS profile 175148
621 S New Ballas Rd, Ste 6017B, Saint Louis, MO 63141
General payments
$150
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Ming Hao of Saint Louis, MO is reported in the CMS Open Payments database as having received $150 across 3 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 44th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $17 | 1 | |
| 2024 | General | $26 | 1 | |
| 2021 | General | $107 | 1 |
Beside peers
- Ming Hao
- Geriatric Medicine median
- Middle half of Geriatric Medicine
- National median
In program year 2025, general payments to Ming Hao were reported at $17. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.
Show as a table
| Year | Ming Hao | Geriatric Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $96 | $28–$339 | $163 |
| 2020 | $0 | $99 | $28–$262 | $114 |
| 2021 | $107 | $94 | $27–$318 | $132 |
| 2022 | $0 | $103 | $34–$338 | $149 |
| 2023 | $0 | $109 | $39–$320 | $160 |
| 2024 | $26 | $125 | $36–$371 | $164 |
| 2025 | $17 | $120 | $37–$350 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 165 drugsPart D claims
11,231
Drug cost
$563,780
Branded share of claims
22.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 492 | $136,465 | |
| Santyl Collagenase Clostridium Hist. | Brand | 71 | $28,766 | |
| Trulicity Dulaglutide | Brand | 32 | $26,481 | |
| Namzaric Memantine Hcl/Donepezil Hcl | Brand | 48 | $14,163 | |
| Myrbetriq Mirabegron | Brand | 54 | $13,745 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 19 | $13,060 | |
| Jardiance Empagliflozin | Brand | 39 | $11,779 | |
| Tradjenta Linagliptin | Brand | 36 | $10,097 | |
| Januvia Sitagliptin Phosphate | Brand | 34 | $9,711 | |
| Autoshield Duo Pen Needle Pen Needle,dual Safety,diabetc | Brand | 189 | $9,111 |
The 10 drugs with the highest cost, of 165 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 10 billing codesPaid by Medicare
$50,342
Medicare patients
196
Services billed
721
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 58% | |
| Depression | 55% | |
| Chronic kidney disease | 53% | |
| Heart failure | 47% | |
| Diabetes | 46% | |
| Ischemic heart disease | 44% | |
| Alzheimer's or dementia | 44% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
1 product · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| REXULTI |
|
$26 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Geriatric Medicine in Missouri
Srinath Tadakamalla
Geriatric Medicine · Harrisonville, MO
Randall Halley
Geriatric Medicine · Columbia, MO
William Knapp
Geriatric Medicine · Florissant, MO
William Rosen
Geriatric Medicine · Springfield, MO
Timothy Wilson
Geriatric Medicine · Kansas City, MO
Mahmoud Mansour
Geriatric Medicine · Columbia, MO
Related records
Geriatric Medicine in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Geriatric Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.